Skip to main content

Advertisement

Influence of variants of Fcg receptor IIA on the European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in psoriatic arthritis

  • 756 Accesses

Introduction

The efficacy of biological therapies currently used in psoriatic arthritis depends not only on their blocking effect on the targeted molecule but also on the affinity of genetically defined variants of the Fc-gamma receptors for the constant portion (Fc fragment of IgG1).

Aim

To determine whether polymorphisms in Fc-gamma receptor IIA influence clinical efficacy in patients with psoriatic arthritis treated with tumor necrosis factor alpha inhibitors.

Patients and methods

The study population comprised 110 patients (52.7% males and 47.3% females) with psoriatic arthritis refractory to 15 mg or more of methotrexate/week. Infliximab (33.6%), etanercept (50.9%) or adalimumab (15.5%) were initiated, and patients were evaluated after 12 and 24 weeks using the EULAR response criteria. Genotyping of FCGR IIA-H131R polymorphism was performed by allele-specific PCR and PCR sequence-based typing. The chi-square test was used to compare response rates across Fc-gamma receptor IIA genotype.

Results

No significant differences were found at 12 and 24 weeks in EULAR responses between patients with high affinity alleles (FCGRIIA HH/HR) and patients with low affinity alleles (FCGRIIA RR) (Tables 1 and 2). However, there was a trend to a better response among patients with high affinity alleles.

Table 1 12 weeks EULAR Response FCGRIIA
Table 2 24 weeks EULAR response FCGRIIA

Conclusion

These results suggest that FCGR IIA-H131R polymorphism has low influence in the clinical efficacy of anti-TNF therapies in patients with psoriatic arthritis. Although different to previously reported results in rheumatoid arthritis[1], these results can be explained because of the better and more prolonged response to anti-TNF therapy in psoriatic arthritis than in rheumatoid arthritis. In addition, in this study we analyzed patients with three different anti-TNF-alpha therapies.

References

  1. 1.

    Cañete JD: . Ann Rheum Dis. 2009, 68: 1547-52. 10.1136/ard.2008.096982.

Download references

Author information

Correspondence to J Ramirez.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Ramirez, J., Fernadez-Sueiro, J.L., Lopez, R. et al. Influence of variants of Fcg receptor IIA on the European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in psoriatic arthritis. J Transl Med 8, P38 (2010) doi:10.1186/1479-5876-8-S1-P38

Download citation

Keywords

  • Infliximab
  • Etanercept
  • Adalimumab
  • Psoriatic Arthritis
  • EULAR Response